DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

with onchocercal ocular involvement. Br J Ophthalmol, 1988,
72:561–569.
Osei-Atweneboana MY, Eng JK, Boakye DA, et al. Prevalence
and intensity of Onchocerca volvulus infection and efficacy of
ivermectin in endemic communities in Ghana: A two-phase
epidemiological study. Lancet, 2007, 369:2021–2029.
Ottesen EA, Ramachandran CP. Lymphatic filariasis infection and
disease: Control strategies. Parasitol Today, 1995, 11:129–131.
Ottesen EA, Ismail MM, Horton J. The role of albendazole in
programmes to eliminate lymphatic filariasis. Parasitol Today,
1999, 15:382–386.
Peixoto CA, Rocha A, Aguiar-Santos A, Florencio MS. The
effects of diethylcarbamazine on the ultrastructure of
Wuchereria bancrofti in vivo and in vitro. Parasitol Res, 2004,
92:513–517.
Pica-Mattocia L, Orcini T, Basso A, et al. Schistosoma mansoni:
lack of correlation between praziquantel-induced intraworm
calcium influx and parasitic death. Exp Parasitol, 2008,
119:332–335.
Prichard R. Anthelmintic resistance. Vet Parasitol, 1994, 54:
259–268.
Redman CA, Robertson A, Fallon PG, et al. Praziquantel: An
urgent and exciting challenge. Parasitol Today, 1996, 12:14–20.
Redondo PA, Alvarez AI, Garcia JL, et al. Presystemic metabolism
of albendazole: Experimental evidence of an efflux
process of albendazole sulfoxide to intestinal lumen. Drug
Metab Dispos, 1999, 27:736–740.
Roberts LJ, Huffam SE, Walton SF, Currie BJ. Crusted scabies:
Clinical and immunological findings in seventy-eight patients
and a review of the literature. J Infect, 2005, 50:375–381.
Robertson SJ, Pennington AJ, Evans AM, Martin RJ. The action
of pyrantel as an agonist and an open-channel blocker at
acetylcholine receptors in isolated Ascaris suum muscle vesicles.
Eur J Pharmacol, 1994, 271:273–282.
Roos MH. The role of drugs in the control of parasitic nematode
infections: Must we do without? Parasitology, 1997, 114(suppl):
S137–S144.
Saba R, Korkmaz M, Inan D, et al. Human fascioliasis. Clin
Microbiol Infect, 2004, 10:385–387.
Sabrosa NA, de Souza EC. Nematode infections of the eye:
Toxocariasis and diffuse unilateral subacute neuroretinitis.
Curr Opin Ophthalmol, 2001, 12:450–454.
Salinas R, Prasad K. Drugs for treating neurocysticercosis (tapeworm
infection of the brain). Cochrane Database Syst Rev,
2000, 2:CD000215.
Sangster NC, Gill J. Pharmacology of anthelmintic resistance.
Parasitol Today, 1999, 15:141–146.
Schaeffer JM, Haines HW. Avermectin binding in
Caenorhabditis elegans. A two-state model for the avermectin
binding site. Biochem Pharmacol, 1989, 38:2329–2338.
Schantz PM. Editorial response: Treatment of cystic
echinococcosis—improving but still limited. Clin Infect Dis,
1999, 29:310–311.
Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the
mouse mdr1a P-glycoprotein gene leads to a deficiency in the
blood-brain barrier and to increased sensitivity to drugs. Cell,
1994, 77:491–502.
Schwab AE, Boakye DA, Kyelem D, Prichard RK. Detection of
benzimidazole resistance-associated mutations in the filarial
nematode Wuchereria bancrofti and evidence for selection by
albendazole and ivermectin combination treatment. Am J Trop
Med Hyg, 2005, 73:234–238.
Sharghi N, Schantz PM, Caramico L, et al. Environmental exposure
to Toxocara as a possible risk factor for asthma: A clinicbased
case-control study. Clin Infect Dis, 2001, 32:
E111–E116.
Shoop WL, Ostlind DA, Roher SP, et al. Avermectins and milbemycins
against Fasciola hepatica: In vivo drug efficacy and in
vitro receptor binding. Int J Parasitol, 1995, 25:923–927.
Spiro RC, Parsons WG, Perry SK, et al. Inhibition of posttranslational
modification and surface expression of a
melanoma-associated chondroitin sulfate proteoglycan by
diethylcarbamazine or ammonium chloride. J Biol Chem,
1986, 261:5121–5129.
Steinmann P, Keiser J, Bos R, et al. Schistosomiasis and water
resources development: Systematic review, meta-analysis, and
estimates of people at risk. Lancet Infect Dis, 2006,
6:411–425.
Symposium. (Various authors.) Biltricide symposium on
African schistosomiasis. (Classen HG, Schramm V, eds.)
Arzneimittelforschung, 1981, 31:535–618.
Taylor MJ, Hoerauf A. A new approach to the treatment of filariasis.
Curr Opin Infect Dis, 2001, 14:727–731.
Urbani C, Albonico M. Anthelminthic drug safety and drug
administration in the control of soil-transmitted helminthiasis
in community campaigns. Acta Trop, 2003, 86:215–223.
Venkatesan P. Albendazole. J Antimicrob Chemother, 1998, 41:
145–147.
World Health Organization. Prevention and Control of
Schistosomiasis and Soil-Transmitted Helminthiasis, Report
of a WHO Expert Committee. WHO Technical Report Series
912, 2002, Geneva.
World Health Organization. Preventive Chemotherapy in Human
Helminthiasis. Coordinated use of anthelminthic drugs in control
interventions: A manual for health professionals and programmatic
managers. WHO, 2006.
Wilmshurst JM, Robb SA. Can mebendazole cause lateralized
occipital seizures? Eur J Paediatr Neurol, 1998, 2:323–324.
Xiao SH, Catto BA, Webster LT Jr. Effects of praziquantel on
different developmental stages of Schistosoma mansoni in
vitro and in vivo. J Infect Dis, 1985, 151:1130–1137.
Xu M, Molento M, Blackhall W, et al. Ivermectin resistance in
nematodes may be caused by alteration of P-glycoprotein
homolog. Mol Biochem Parasitol, 1998, 91:327–335.
Zeng Z, Andrew NW, Arison BH, et al. Identification of
cytochrome P4503A4 as the major enzyme responsible for the
metabolism of ivermectin by human liver microsomes.
Xenobiotica, 1998, 28:313–321.
Zufall F, Franke C, Hatt H. The insecticide avermectin B 1a
activates
a chloride channel in crayfish muscle membrane. J Exp
Biol, 1989, 142:191–205.
1461
CHAPTER 51
CHEMOTHERAPY OF HELMINTH INFECTIONS